Currently, blood-based screening is mostly appropriate for high-risk groups, such as: Prostate cancer: Men over 50 may ...

By analysing DNA from blood samples, Tvaster Genkalp is working to make cancer diagnostics more accessible, accurate, and ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Myriad Genetics will present ... to advancing personalized cancer care and addressing unmet clinical needs. The mention that no clinically-utilized prognostic markers currently exist to identify ...

Hepatocellular carcinoma (HCC) represents the most prevalent ... circRNAs have been observed in several genetic studies to play a vital role in the initiation and progression of malignancy.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered. Based on new findings in ...

Although we have yet to identify a definitive genetic marker for TGCTs, studies like this pave the way for more personalised approaches to cancer prevention and treatment.” The lack of replication in ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver disease, according to findings in JAMA Internal Medicine.

We aim to develop non-viral nanocarriers to deliver ribonucleoproteins (RNP) targeting Glypican-3 (GPC3) and investigate the biological and immunological therapeutic effects from CRISPR-Cas9 GPC3 gene ...